The Precision Peptide Company Inc. PNGAF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 120.50K | 78.90K | 66.90K | 35.90K | 5.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 120.50K | 78.90K | 66.90K | 35.90K | 5.10K |
| Cost of Revenue | 56.30K | 37.60K | 25.40K | 20.00K | 2.50K |
| Gross Profit | 64.10K | 41.20K | 41.40K | 15.80K | 2.60K |
| SG&A Expenses | 3.33M | 2.63M | 2.48M | 1.58M | 1.14M |
| Depreciation & Amortization | 33.30K | 33.30K | 33.30K | 33.30K | -200.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.47M | 2.76M | 2.58M | 1.66M | 1.16M |
| Operating Income | -3.35M | -2.68M | -2.52M | -1.62M | -1.15M |
| Income Before Tax | -5.12M | -4.32M | -4.16M | -3.29M | -1.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.12 | -4.32 | -4.16 | -3.29 | -1.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.12M | -4.32M | -4.16M | -3.29M | -1.19M |
| EBIT | -3.35M | -2.68M | -2.52M | -1.62M | -1.15M |
| EBITDA | -3.27M | -2.60M | -2.46M | -1.57M | -1.14M |
| EPS Basic | -0.11 | -0.10 | -0.11 | -0.10 | -0.09 |
| Normalized Basic EPS | -0.05 | -0.04 | -0.04 | -0.04 | -0.06 |
| EPS Diluted | -0.11 | -0.10 | -0.11 | -0.10 | -0.09 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.04 | -0.04 | -0.06 |
| Average Basic Shares Outstanding | 176.51M | 156.70M | 133.14M | 100.36M | 62.89M |
| Average Diluted Shares Outstanding | 176.51M | 156.70M | 133.14M | 100.36M | 62.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |